Nancy Wasserbauer Kingston, DO
Allergy & Immunology · Rocky River, OHNPI 1922022524
Payments from drug & device makers
Across 553 payments — averaging $462.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$140K
- AstraZeneca$87K
- Biocryst US Sales Co., LLC$23K
- Genentech USA, Inc.$3K
- CSL Behring$612
- Sanofi$383
- plus $2K from 30 others
What the payments were for
- Consulting fees$4,6422%
- Speaking & faculty fees$228,31589%
- Travel & lodging$10,5124%
- Food & beverage$12,1285%
- Education$2110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 225 | $139,770 |
| AstraZeneca | 147 | $86,543 |
| Biocryst US Sales Co., LLC | 37 | $22,720 |
| Genentech USA, Inc. | 13 | $3,497 |
| CSL Behring | 28 | $612 |
| Sanofi | 12 | $383 |
| Regeneron Healthcare Solutions, Inc. | 10 | $338 |
| Pfizer | 13 | $274 |
| Novartis | 11 | $257 |
| Optinose US, Inc. | 7 | $248 |
| Kyowa Kirin, Inc. | 2 | $118 |
| Phadia US Inc. | 1 | $117 |
| Verona Pharma, Inc. | 5 | $109 |
| Lilly USA, LLC | 1 | $81 |
| Bio Products Laboratory USA, Inc. | 4 | $77 |
| Teva Pharmaceuticals USA, Inc. | 4 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $75 |
| LEO Pharma Inc. | 3 | $74 |
| Amgen | 4 | $70 |
| Pharming Healthcare, Inc. | 3 | $58 |
| Blueprint Medicines Corporation | 2 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $29 |
| Kaleo, Inc. | 2 | $23 |
| Ionis Pharmaceuticals, Inc. | 1 | $23 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Insmed, Inc. | 1 | $22 |
| ADMA Biomanufacturing LLC | 2 | $22 |
| Galderma Laboratories, L.p. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $18 |
| Grifols USA, LLC | 1 | $15 |
| Alk-abello, Inc | 1 | $15 |
| GC Biopharma USA, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $13 |
| Greer Laboratories, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$255,808 in reported general payments places this provider in the 90th percentile of 128 allergy & immunology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 50 | $171,224 |
| NucalaMepolizumab | 15 | $169,915 |
| XembifyImmune Globulin,gamma(Igg)klhw | 13 | $91,494 |
| XolairOmalizumab | 25 | $82,873 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $26,967 |
| Breo ElliptaFluticasone/Vilanterol | 44 | $20,419 |
| Epinephrine | 25 | $7,594 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $6,169 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $2,673 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 58 | $2,110 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $1,946 |
| Ipratropium Bromide | 40 | $1,267 |
| Azelastine Hcl | 44 | $1,073 |
| Fluticasone Propionate | 46 | $478 |
| Montelukast Sodium | 85 | $403 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $139,770 | $217,30186 claims |
| CSL BehringHizentra | $612 | $171,22450 claims |
| Grifols USA, LLCXembify | $15 | $91,49413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 128 allergy & immunology providers in Ohio.
Other allergy & immunology in Rocky River
- Sridhar GuduriDublin$11.3M
- Donald McNeilColumbus$4.8M
- Jonathan BernsteinCincinnati$4.5M
- Syed RehmanToledo$3.6M
- David BernsteinCincinnati$2.7M
- Justin GreiweCincinnati$1M
- Sheharyar DurraniCincinnati$953K
- Juan AboniaCincinnati$515K
- Adam UpdegraffToledo$379K
- Gordon MyersCincinnati$346K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.